These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 15378440

  • 1. Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits.
    Etienne M, Croisier D, Charles PE, Lequeu C, Piroth L, Portier H, Drlica K, Chavanet P.
    J Infect Dis; 2004 Oct 15; 190(8):1472-5. PubMed ID: 15378440
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S, Van Heirstraeten L, Lammens C, Chapelle S, Goossens H.
    J Antimicrob Chemother; 2009 May 15; 63(5):886-94. PubMed ID: 19279051
    [Abstract] [Full Text] [Related]

  • 4. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ, Walters M, Hisanaga T, Zhanel GG, Hoban DJ.
    Antimicrob Agents Chemother; 2004 Oct 15; 48(10):3954-8. PubMed ID: 15388458
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
    Deryke CA, Du X, Nicolau DP.
    J Antimicrob Chemother; 2006 Sep 15; 58(3):601-9. PubMed ID: 16857688
    [Abstract] [Full Text] [Related]

  • 8. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
    Sierra JM, Cabeza JG, Ruiz Chaler M, Montero T, Hernandez J, Mensa J, Llagostera M, Vila J.
    Clin Microbiol Infect; 2005 Sep 15; 11(9):750-8. PubMed ID: 16104991
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.
    Schurek KN, Adam HJ, Siemens CG, Hoban CJ, Hoban DJ, Zhanel GG.
    J Antimicrob Chemother; 2005 Oct 15; 56(4):769-72. PubMed ID: 16126779
    [Abstract] [Full Text] [Related]

  • 13. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
    Schafer J, Hovde LB, Simonson D, Rotschafer JC.
    Diagn Microbiol Infect Dis; 2008 Feb 15; 60(2):155-61. PubMed ID: 17910998
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy.
    Urban C, Rahman N, Zhao X, Mariano N, Segal-Maurer S, Drlica K, Rahal JJ.
    J Infect Dis; 2001 Sep 15; 184(6):794-8. PubMed ID: 11517444
    [Abstract] [Full Text] [Related]

  • 16. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing.
    Zinner SH, Lubenko IY, Gilbert D, Simmons K, Zhao X, Drlica K, Firsov AA.
    J Antimicrob Chemother; 2003 Oct 15; 52(4):616-22. PubMed ID: 12951352
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Mutation window for the "pneumococcus-fluoroquinolone" couple. Contribution of experimental models].
    Chavanet P, Croisier D.
    Med Mal Infect; 2006 Oct 15; 36(11-12):614-24. PubMed ID: 17095175
    [Abstract] [Full Text] [Related]

  • 19. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.
    Okumura R, Hirata T, Onodera Y, Hoshino K, Otani T, Yamamoto T.
    J Antimicrob Chemother; 2008 Jul 15; 62(1):98-104. PubMed ID: 18390884
    [Abstract] [Full Text] [Related]

  • 20. Fluoroquinolone-resistant Streptococcus pneumoniae.
    Pletz MW, Fugit RV, McGee L, Glasheen JJ, Keller DL, Welte T, Klugman KP.
    Emerg Infect Dis; 2006 Sep 15; 12(9):1462-3. PubMed ID: 17073107
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.